Preliminary Genotoxicity Assessment of Calcium Phosphate Cement Incorporated with Palm Tocotrienol Using Bacterial...

Calcium phosphate cement is widely used in bone repair due to its biocompatibility and structural similarity to natural bone. Prior research has shown that CPC supports osteoconduction and tissue regeneration. However, the addition of phytochemicals like palm tocotrienol introduces new variables in material safety. No prior work had resolved whether these compounds might pose genotoxic risks. This uncertainty drives the need for systematic testing. The bacterial reverse mutation assay is a standard tool for preliminary genotoxicity screening. While CPC’s biocompatibility is well established, its mutagenic potential remains less explored. The study addresses a gap in understanding how functionalised CPC behaves in mutagenicity tests. This work builds on prior knowledge of CPC’s clinical use but introduces a novel safety concern.

The aim of this study was to assess the mutagenic potential of calcium phosphate cement and its tocotrienol-enriched variant. The specific problem addressed is whether phytochemical incorporation alters CPC’s safety profile. The authors sought to exclude genotoxic risks associated with CPC-T3. This investigation focused on bacterial reverse mutation as a preliminary screening method. The study’s motivation stems from the need to ensure CPC-T3 is safe for medical use. No prior studies had evaluated this specific combination of CPC and palm tocotrienol. The research question is whether CPC-T3 induces mutagenic activity in bacterial strains. The findings aim to inform further translational development of CPC-based implants.

The mutagenic potential of CPC and CPC-T3 was evaluated using a bacterial reverse mutation assay. Five bacterial strains were selected for testing: Salmonella typhimurium TA100, TA98, TA1535, TA1537, and Escherichia coli WP2 trp uvrA. The assay was conducted under both non-metabolic and metabolic activation conditions. Revertant colony counts were measured at multiple concentrations of the test materials. Mutagenicity ratios were calculated relative to the negative control. The study followed OECD Test Guideline No. 471 for mutagenicity screening. Controls were included to validate the sensitivity and reliability of the assay. The experimental design focused on detecting reproducible and dose-dependent mutagenic effects.

Neither CPC nor CPC-T3 induced reproducible increases in revertant colony counts across all bacterial strains. No concentration-dependent trends were observed in the mutagenicity ratios. Isolated elevations were detected at certain concentrations but lacked dose-response relationships. These findings did not meet the OECD criteria for a positive mutagenic response. The negative controls performed as expected, confirming the assay’s validity. Positive controls also showed appropriate mutagenic activity. The inclusion of palm tocotrienol did not alter CPC’s mutagenicity profile. The results suggest that CPC and CPC-T3 are not mutagenic under the tested conditions.

The authors concluded that CPC and CPC-T3 showed no evidence of mutagenic activity in the bacterial reverse mutation assay. These findings represent preliminary genotoxicity screening rather than definitive safety confirmation. The study does not propose that CPC-T3 is inherently safe for all applications. The lack of mutagenic activity supports further investigation into CPC-T3’s biocompatibility. The authors suggest that mammalian genotoxicity and in vivo studies are necessary next steps. No essential role for palm tocotrienol in mutagenicity was claimed. The results do not imply that CPC-T3 is fully safe for implantation. The authors recommend additional testing to support translational development.